BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/25/2025 4:18:56 PM | Browse: 16 | Download: 77
 |
Received |
|
2024-09-12 08:11 |
|
Peer-Review Started |
|
2024-09-12 08:11 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-01-16 12:33 |
|
Revised |
|
2025-01-25 06:11 |
|
Second Decision |
|
2025-02-13 02:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-02-13 07:06 |
|
Articles in Press |
|
2025-02-13 07:06 |
|
Publication Fee Transferred |
|
2025-01-26 10:02 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-07 02:21 |
|
Publish the Manuscript Online |
|
2025-03-25 16:18 |
| ISSN |
1948-5204 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jian-Lin Lu, Yuan Cheng, Zi-Ling Xu, Gui-Xiang Qian, Ming-Tong Wei and Wei-Dong Jia |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Key Research and Development Projects of Anhui Province |
202104j07020048 |
| National Key Research and Development Program of China |
2022YFA1304504 |
|
| Corresponding Author |
Wei-Dong Jia, MD, PhD, Professor, Department of Hepatic Surgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, China. jwd1968@ustc.edu.cn |
| Key Words |
Hepatocellular carcinoma; Hepatitis B virus; Postoperative adjuvant therapy; Immune checkpoint inhibitors; Anti-angiogenesis |
| Core Tip |
The postoperative combined therapy with anti-programmed death 1/anti-programmed death ligand 1 and anti-vascular endothelial growth factor receptor agents has not been shown to be effective but not significant in reducing early recurrence in patients with hepatitis B virus-associated hepatocellular carcinoma. And thorough evaluation and close monitoring of liver function and hepatitis B-related markers in patients with hepatitis B virus-associated hepatocellular carcinoma are critical when implementing this combined treatment approach. |
| Publish Date |
2025-03-25 16:18 |
| Citation |
<p>Lu JL, Cheng Y, Xu ZL, Qian GX, Wei MT, Jia WD. Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma. <i>World J Gastrointest Oncol</i> 2025; 17(4): 101371</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/101371.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.101371 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
